Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN2A | Q99250 | 7/20 | 0.74 |
| ▸ | SCN5A | Q14524 | 5/20 | 0.74 |
| ▸ | BACE1 | P56817 | 4/20 | 0.55 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.51 |
| ▸ | HTR7 | P34969 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | PLK1 | P53350 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.45 |
| ▸ | TPH1 | P17752 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4629007 | 0.89 | SCN2A (0.77) | SCN2ASCN5ABACE1PARP10HTR7 | |
| SCHEMBL4628404 | 0.85 | SCN2A (1.00) | SCN2ASCN5ABACE1HTR7LMNA | |
| SCHEMBL4629287 | 0.78 | HPGD (0.55) | PARP10MEN1KMT2AMAPTPLK1 | |
| SCHEMBL6702037 | 0.77 | SCN2A (0.69) | SCN2ASCN5ABACE1HTR7MEN1 | |
| SCHEMBL4628764 | 0.75 | SCN2A (0.85) | SCN2ASCN5AMAPTPLK1 | |
| SCHEMBL4628970 | 0.73 | SCN2A (0.94) | SCN2ASCN5AKMT2AMAPT | |
| SCHEMBL4628495 | 0.72 | SCN5A (1.00) | SCN2ASCN5AMAPT | |
| SCHEMBL4628794 | 0.72 | SCN2A (0.74) | SCN2ASCN5ABACE1MEN1KMT2A | |
| SCHEMBL28912681 | 0.71 | PLK1 (0.72) | SCN2ASCN5AMEN1KMT2AMAPT | |
| SCHEMBL4628571 | 0.70 | SCN2A (0.72) | SCN2ASCN5APARP10MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1032556-B1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE | WYETH CORP (US) | 2007-12-19 | — | — | EP | claimed |
| US-7041702-B1 | Pharmaceutically active compounds and methods of use | SCION PHARMACEUTICALS, INC. (US) | 2006-05-09 | — | — | US | claimed |
| EP-1918272-A1 | Pharmaceutically active compounds and methods of use | Wyeth a Corporation of the State of Delaware (US) | 2008-05-07 | — | — | EP | disclosed |
| EP-1032556-B1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE | WYETH CORP (US) | 2007-12-19 | — | — | EP | disclosed |
| US-20060270741-A1 | Pharmaceutically active compounds and methods of use | SCION PHARMACEUTICALS, INC. (US) | 2006-11-30 | — | — | US | disclosed |
| US-7041702-B1 | Pharmaceutically active compounds and methods of use | SCION PHARMACEUTICALS, INC. (US) | 2006-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270741-A1 | Pharmaceutically active compounds and methods of use | GBA1, CTSA, GAA | SCN2A 1613/4885SCN5A 1196/4885BACE1 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.